InQB8 Medical Technologies LLC and Peijia Medical Limited Report Successful First-in-Human (FIH) Implantation of MonarQ Transcatheter Tricuspid Valve Replacement (TTVR) System in The United States of America
InQB8 Medical Technologies LLC and Peijia Medical Limited Report Successful First-in-Human (FIH) Implantation of MonarQ Transcatheter Tricuspid Valve Replacement (TTVR) System in The United States of America
WINCHESTER, Mass. and SUZHOU, China, Dec. 5, 2023 /PRNewswire/ -- inQB8 Medical Technologies LLC (inQB8), in partnership with Peijia Medical Limited (Peijia, (9996.HK)), announced that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve (TTV) in a patient suffering from torrential tricuspid regurgitation (TR) and no other available therapy available to her. The trans-jugular TTVR procedure was performed on December 1, 2023, on compassionate grounds at the UPENN Presbyterian Medical Center by cardiac surgeon Professor. Dr. Wilson V. Szeto, interventional cardiologist Dr. Jean Chang MD., echo cardiologist Dr. Roy MD., and the attending anesthesiologist Dr. Thal. Prof. Dr. Fabien Praz from Switzerland, and Lars Sondergaard MD. were in attendance sharing their expertise. Arshad Quadri, MD. Executive Chairman and CMO of inQB8 proctored the case.
马萨诸塞州温彻斯特和中国苏州,2023 年 12 月 5 日 /PRNewswire/ — inqb8 医疗技术有限责任公司(inQb8)与培佳医疗有限公司(Peijia,(9996.HK))合作宣布,它已成功向一名患有三尖瓣急性反流的患者植入 monarQ 经导管三尖瓣膜 (TTV) (TR) 而且她没有其他可用的疗法。经颈静脉 TTVR 手术于 2023 年 12 月 1 日在宾夕法尼亚大学长老会医学中心由心脏外科教授出于同情心进行。Wilson V. Szeto 博士、介入心脏病专家 Jean Chang 博士、超声心脏病专家 Roy MD. 和主治麻醉师 Thal 博士。来自瑞士的法比安·普拉兹教授和拉尔斯·桑德加德医学博士出席了会议,分享了他们的专业知识。Arshad Quadri,医学博士InQb8的执行主席兼首席营销官监督了此案。
"We successfully implanted the MonarQ TTV in the suitable tricuspid region in this extremely high risk patient. My team and I are grateful and excited to work with Dr. Quadri and his team from inQB8, who provided this very exciting MonarQ TTV implantation therapy option to this patient," said Dr. Wilson Szeto. "Due to multiple risk factors and anatomical restrictions, neither traditional tricuspid valve surgery, nor edge-to-edge transcatheter tricuspid repair were options for this patient. Through careful review and consideration within our team, we determined that TTVR with the MonarQ TTV will alleviate symptoms and provide an improved quality of life for this extremely high risk patient whose only other option would have been hospice. The valve was implanted successfully implanted with a dramatic reduction of her torrential tricuspid regurgitation," added Dr. Szeto.
“我们成功地将MonarQ TTV植入了这名极高风险患者的相应三尖瓣区域。我和我的团队很感激也很高兴能与来自inQb8的Quadri博士和他的团队合作,他们为这位患者提供了这种非常令人兴奋的MonarQ TTV植入疗法,” Wilson Szeto博士说。“由于多种风险因素和解剖学限制,无论是传统的三尖瓣手术,还是边缘到边缘的经导管三尖瓣修复术,都不是该患者的选择。通过我们团队内部的仔细审查和考虑,我们确定配备MonarQ TTV的TTVR将缓解症状并改善这名极高风险患者的生活质量,而他唯一的选择就是临终关怀。瓣膜成功植入,显著减少了她的三尖瓣反流。” 塞托博士补充说。
"I am honored and delighted to work with Dr. Wilson Szeto and his team at the UPENN Presbyterian Medical Center in this next chapter of transcatheter valve therapy. The MonarQ TTV has a unique BioDynamic attachment system that utilizes and preserves the heart's natural motion by securing the implant to the native leaflets. The Biodynamic motion distribute systolic loads, and a multilobed atrial disc aids in fixation to the native valve and minimizes paravalvular leak. We are very grateful to the patient and her family for consenting to this new type of valve replacement therapy," said Arshad Quadri, M.D., cardiac surgeon and co-founder, Executive Chairman, and CMO of inQB8.
“我很荣幸也很高兴能与威尔逊·塞托博士及其团队在UPENN长老会医学中心合作,开启经导管瓣膜治疗的下一个篇章。MonarQ TTV 具有独特的 BioDynamic 连接系统,通过将植入物固定在原生小叶上,利用并保持心脏的自然运动。生物动力学运动可分配收缩压负荷,多叶心房盘有助于固定原生瓣膜并最大限度地减少旁瓣膜渗漏。我们非常感谢患者及其家人同意这种新型的瓣膜替代疗法。” 心脏外科医生、InQb8联合创始人、执行董事长兼首席营销官Arshad Quadri说。
"In the past few years, the need for a TTVR solution has become increasingly clear. As Peijia looks to expand its presence globally and build its structural heart portfolio, our combined investment in inQB8 and the MonarQ TTVR technology was a natural choice," said Dr. Michael Zhang, Peijia's Chairman & CEO. "The successful FIH MonarQ implantation in USA marks an exciting step in bringing this life-saving and life-enhancing technology to more and more patients around the world."
“在过去的几年中,对TTVR解决方案的需求变得越来越明显。在Peijia希望扩大其全球影响力并建立其结构性心脏投资组合之际,我们对inQb8和MonarQ TTVR技术的合并投资是自然而然的选择。” 培佳董事长兼首席执行官Michael Zhang博士说。“美国FIH MonarQ的成功植入标志着在将这种拯救生命和增强生命的技术带给全球越来越多的患者方面迈出了激动人心的一步。”
About inQB8
关于 inQb8
inQB8 is a privately held medical device incubator headquartered in Massachusetts with additional offices in Irvine, Calif. It is the second collaboration between Dr. Arshad Quadri, MD. and J. Brent Ratz, MBA, whose partnership began 16 years ago with the co-founding of CardiAQ Valve Technologies, the world's first trans-septal Transcatheter Mitral Valve Replacement (TMVR) system. inQB8 focuses on developing novel international solutions for major cardiovascular diseases including structural heart issues, aortic disease and heart failure, accelerating projects through prototyping, bench, and pre-clinical testing until they are ready to be acquired or advanced as separate stand-alone cardiovascular start-ups. In June 2021, Peijia announced a strategic partnership with inQB8 and agreed to acquire the MonarQ TTVR technology, which inQB8 continues to develop on its behalf.
InQb8 是一家私人控股的医疗器械孵化器,总部位于马萨诸塞州,在加利福尼亚州尔湾设有办事处。这是医学博士Arshad Quadri博士和工商管理硕士J.Brent Ratz的第二次合作,后者的合作始于16年前,当时共同创立了世界上第一个经隔膜经导管二尖瓣置换术(TMVR)系统 Cardiaq Valve Technologies。inqb8 专注于为包括结构性心脏问题、主动脉疾病和心力衰竭在内的重大心血管疾病开发新的国际解决方案,通过原型设计、台架设计加快项目进度临床前测试,直到它们准备好收购或单独进行推进心血管初创企业。2021年6月,Peijia宣布与inqb8建立战略合作伙伴关系,并同意收购MonarQ TTVR技术,inqb8将继续代表其开发该技术。
About Peijia
关于培佳
Peijia was established in 2012 and is headquartered in Suzhou, China. Peijia focuses on the high-growth interventional procedural medical device market in China, and aims to become a world-renowned medical device platform that provides comprehensive treatment solutions for structural heart and neurovascular diseases.
培佳成立于2012年,总部位于中国苏州。培佳专注于中国高增长的介入手术医疗器械市场,旨在成为世界知名的医疗器械平台,为结构性心脏和神经血管疾病提供全面的治疗解决方案。
Any forward-looking statements are subject to risks and uncertainties such as those described in Peijia's periodic reports on file with the HKEx. Actual results may differ materially from anticipated results.
任何前瞻性陈述都受到风险和不确定性的影响,例如Peijia向香港交易所存档的定期报告中描述的风险和不确定性。实际结果可能与预期结果存在重大差异。
Caution: The MonarQ TTVR system is in the early phases of development. It will not be available for clinical trials until further notice and is NOT available for sale.
注意:MonarQ TTVR 系统处于开发的早期阶段。除非另行通知,否则它将无法用于临床试验,并且不可出售。